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Background: Hypogammaglobulinemia may be part of several different immunological or malignant conditions,
and its origin is not always obvious. Furthermore, although autoimmune cytopenias are known to be associated
with common variable immunodeficiency (CVID) and even may precede signs of immunodeficiency, this is not
always recognized. Despite novel insight into the molecular immunology of common variable immunodeficiency,
several areas of uncertainty remain. In addition, the full spectrum of immunological effects of the B cell depleting
anti-CD20 antibody Rituximab has not been fully explored. To our knowledge this is the first report of development
of CVID in a patient with normal immunoglobulin prior to Rituximab treatment.
Case presentation: Here we describe the highly unusual clinical presentation of a 34-year old Caucasian male with
treatment refractory immune thrombocytopenic purpura and persistent lymphadenopathy, who was
splenectomized and received multiple courses of high-dose corticosteroid before treatment with Rituximab resulted
in a sustained response. However, in the setting of severe pneumococcal meningitis, hypogammaglobulinemia was
diagnosed. An extensive immunological investigation was performed in order to characterize his immune status,
and to distinguish between a primary immunodeficiency and a side effect of Rituximab treatment. We provide an
extensive presentation and discussion of the literature on the basic immunology of CVID, the mechanism of action
of Rituximab, and the immunopathogenesis of hypogammaglobulinemia observed in this patient.
Conclusions: We suggest that CVID should be ruled out in any patient with immune cytopenias in order to avoid
diagnostic delay. Likewise, we stress the importance of monitoring immunoglobulin levels before, during, and after
Rituximab therapy to identify patients with hypogammaglobulinemia to ensure initiation of immunoglobulin
replacement therapy in order to avoid life-threatening invasive bacterial infections. Recent reports indicate that
Rituximab is not contra-indicated for the treatment of CVID-associated thrombocytopenia, however concomitant
immunoglobulin substitution therapy is of fundamental importance to minimize the risk of infections. Therefore,
lessons can be learned from this case report by clinicians caring for patients with immunodeficiencies,
haematological diseases or other autoimmune disorders, particularly, when Rituximab treatment may
be considered.
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Humoral immunity is dependent upon a full repertoire of
mature B-lymphocytes capable of adequately mounting a
primary and secondary immune response. Lack of this will
invariably lead to severe bacterial infections as can be eva-
luated by the disease spectrum in inborn and acquired im-
munodeficiencies. Regarding the former, common variable
immunodeficiency (CVID) is a heterogeneous entity cha-
racterized by varying degrees of hypogammaglobulinemia
and recurrent bacterial infections. Patients with CVID
also experience an increased risk of granulomatous
and autoimmune manifestations as well as malignancy
[1,2]. Autoimmune manifestations, among which Im-
mune thrombocytopenic purpura (ITP) and auto-
immune hemolytic anemia (AIHA) are the most frequent,
occur in as many as 20–40% of CVID patients and often
precede symptoms of immune deficiency [3]. Cytopenias,
and particularly ITP, may therefore be the initial presenta-
tion of CVID, and recognizing a possible underlying im-
munodeficiency may have important implications for the
choice of treatment.
Acquired hypogammaglobulinaemia is typically associ-
ated with malignant disorders in the B-cell lineage such as
B- cell chronic lymphocytic leukemia (B-CLL), B-cell de-
rived non-Hodgkin’s lymphomas (NHL) or multiple mye-
loma. Here, progressive disease in combination with
cytoreduction leads to secondary hypogammaglobulinemia
and ensuing infections. Finally, immunosuppressive the-
rapy targeted at B-cells, e.g. in autoimmune disorders can
lead to similar clinical presentations, admittedly often to a
lesser extent.
ITP is a condition, in which the challenge is to alleviate
thrombocytopenia without inducing severe immunosup-
pression. Thus, while most cases can be easily treated and
will not recur, others will relapse without any apparent
trigger and will turn out to be increasingly difficult to treat.
The current management of ITP usually consists of an ini-
tial course of corticosteroids. Should the condition recur
and corticosteroid therapy be either not effective or not
feasible, high-dose immunoglobulins, perhaps followed by
splenectomy used to be accepted standard therapy. How-
ever, given that a number of patients refractory to standard
immunosuppressive treatment have been successfully
treated with Rituximab, an anti-CD20 chimeric antibody
depleting CD20-expressing B cells in lymphoid tissues and
in the circulation, this regimen is rapidly gaining accept-
ance as the treatment of choice at relapse of ITP [4]. It is
known that repeated courses of Rituximab in NHL patients
generally do not lead to hypogammaglubulinaemia, nor in-
creased frequency of infections. However, the extent and
duration of B cell depletion and effects on immunoglobulin
levels in ITP patients, especially those pretreated with cor-
ticosteroids, high-dose Ig and splenectomy, are not well
described. Furthermore, growing evidence suggest thatRituximab not only depletes cells within the B cell com-
partment, but also may influence T cell immunity [4].
Therefore the long-term effects of Rituximab treatment, in
particular with respect to the immune competence of the
host, need to be better explored.
Here we describe an ITP patient, in whom Rituximab
was instituted some 24 years after onset, and in whom the
prior therapy might have predisposed him to the persis-
tent hypogammaglobulinemia observed, which resulted in
a severe infection requiring immunoglobulin replacement
therapy.
We review the literature on CVID, ITP, and Rituximab
and discuss whether this patient’s hypogammaglobulinemia
was due to underlying CVID, or alternatively was induced
directly by Rituximab treatment.
Case presentation
A 34-year old man was referred to the International Center
of Immunodeficiency Diseases (ICID) in January 2011 with
hypogammaglobulinemia diagnosed in the context of se-
vere pneumococcal meningitis, for which he had been hos-
pitalized in the intensive care unit the previous month.
The patient, who was splenectomized due to ITP, had ex-
perienced a very rapid and aggressive clinical course with
invasive disease despite the use of oral penicillin prior to
admission. In the intensive care unit he had been treated
with standard antibiotic therapy, including intravenous
penicillin and ceftriaxone as well as dexamethasone. He
had made an uneventful recovery without neurological defi-
cits. However, persistently reduced levels of serum IgG of
2.6 g/L (6.1 g/L - 14.9 g/L) and IgA of 0.14 g/L (0.80 g/L –
3.90 g/L) but normal IgM of 0.73 g/L (0.39 g/L – 2.08 g/L)
remained.
Past medical history
The patient had been diagnosed with ITP at 11 years of
age in 1987. At that time, he had severe thrombocytopenia
(3 × 109 cells/L), modest leukopenia (2.2 × 109 cells/L) and
lymphadenopathy. Peripheral blood smear, bone marrow
biopsy, and lymph node biopsy all displayed normal his-
tology. According to his pediatric medical file, he reported
no increased frequency of bacterial infections during child-
hood, and neither relatives nor siblings had any known im-
munodeficiencies or autoimmune diseases. He was treated
with thrombocyte infusions and intravenous immuno-
globulin (0.4 g/kg) followed by a three-week course of
corticosteroid (2 mg/kg) with a resultant rapid increase in
thrombocyte count. Unfortunately, immunoglobulin
levels were not measured at the time. Due to several
relapses of severe thrombocytopenia with each tapering
of corticosteroid treatment, he was subsequently
splenectomized in 1988. Hepato-splenomegaly was ob-
served during the operation, and pathological evalu-
ation of the spleen displayed hyperplasia without
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scintigraphically demonstrated but not removed.
During the following years, he was followed at the Uni-
versity Hospital Department of Hematology, and several
episodes of severe thrombocytopenia accompanied by
bruises and petecchiae occurred, each time responding im-
mediately, but transiently, to high-dose corticosteroid
treatment. Lymph node biopsy due to persistent lymph-
adenopathy again revealed benign hyperplasia. Due to lack
of an acceptable response to repeated courses of high-dose
corticosteroid (100 mg daily), the patient was treated in
January 2009 with four doses of Rituximab (375 mg/m2 iv.)
one week apart. He had an excellent response with
normalization of thrombocyte counts and a lasting re-
sponse, so far for 36 months. Based on the stable platelets
and the fact that the patient was a medical doctor, his con-
tacts with the Hematology Department were restricted to
e-mails based on platelet counts performed twice a year.
Hypogammaglobulinemia, the infectious episode, and its
elucidation
After a vacation in Mallorca spent sailing in December
2010 the patient returned home with an upper respiratory
tract infection as well as diarrhoea and vomiting. The pa-
tient developed high fevers and confusion and was admitted
to the Department of Infectious Diseases, where pneumo-
coccal meningitis was diagnosed. Within a few hours the
patient became unconscious necessitating transfer to the
Intensive Care Unit on mechanical ventilation, where he
received ten days of antibiotic treatment and made a
successful recovery. At presentation in the ICID with
hypogammaglobulinemia in January 2011, it turned out that
the patient had been suffering from several infections du-
ring the past two years, since Rituximab treatment in
January 2009. He reported frequent episodes of upper air-
way infections, (although no sinusitis or pneumonia) and
gastrointestinal symptoms, including almost daily discom-
fort and diarrhoea. According to his pediatric medical file,Figure 1 Laboratory parameters and treatment over time. Plasma IgG
illustrated as percentages of reference lower limit (6.0 g/L, 0.78 g/L, and 15
initiation of IgG substitution therapy (green arrow) are also depicted. Throm
patient’s thrombocytes but undetectable in serum (diamond) are marked. F
pneumococcal polysaccharide-binding IgGs are marked (triangle).he had received appropriate vaccination before the splenec-
tomy, and also reported having followed up correctly on
pneumococcal antibody status and re-vaccination as prescribed.
An extensive immunological evaluation was performed in
an attempt to distinguish between a primary immunodefi-
ciency possibly aggravated by Rituximab treatment or, alter-
natively, hypogammaglobulinemia induced by Rituximab
treatment. The results are summarized below and illus-
trated in Figure 1.
Serum antibody levels
The patient had severely reduced serum IgG (2.6 g/L)
with all subclasses affected except IgG3, and reduced
IgA (0.14 g/L), whereas IgM was normal. Blood tests taken
before Rituximab treatment revealed that selective IgA defi-
ciency was present already in 2007, whereas normal levels
(although only slightly above the lower limit dating back to
2001) of serum IgG had been measured at several
occasions during the period between February 2007 and
January 2009. In addition, low levels of isohaemagglutinins
were present. Thrombocyte-specific antibodies (IgG with
unknown allo-specificity) were present repeatedly in 2001,
2007, and 2008. In January 2009 just prior to Rituximab
infusion membrane-bound but no soluble anti-thrombocyte
antibodies were detectable, but were absent in 2010 and
2011 at several occasions. Finally, in March 2007 he had in-
sufficient pneumococcal antibody levels following latest vac-
cination in February 2001. During the first evaluation in our
department in 2010 he again had insufficient pneumococcal
antibody levels despite vaccination in 2007 as well as in 2009
prior to Rituximab treatment. Antibody levels against
difteria- and tetanus toxin were within normal limits in
December 2010.
B and T cell subsets
The number of B cells in the peripheral blood was evalu-
ated by flow cytometry in 2001 and revealed a normal frac-
tion of CD19/CD20+ cells without evidence of light chain(green), plasma IgA (yellow), and thrombocyte count (blue) are
0 × 10^9/L respectively). Time of Rituximab treatment (red line) and
bocyte-binding IgGs identified in serum (square) or bound to the
inally, time points for measurement of insufficient concentrations of
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revealed a severely reduced fraction (0.1%) of isotype-
switched memory B cells (CD19/20+ IgD- IgM- CD38-
CD27+) (Additional file 1: Table S1). Additionally, selective
reductions in marginal zone-like B cells (CD19/20+ IgD +
IgM+CD38- CD27+) and absence of plasmablasts (CD19+
CD20- IgD- IgM+/− CD38+ CD27+) were observed.
Within the T cell compartment only minor abnormalities
were demonstrated (Additional file 1: Table S1), including a
major, and possibly increased fraction of 15% of CD4-
CD8- double negative T cells (normal range 4–11%) [5,6], a
slightly decreased fraction of naïve cells among CD4 T cells,
and a bias towards a terminally differentiated memory frac-
tion among CD8 T cells. Consistent with this, lymphocyte
proliferation analyses in response to a range of mitogens
(PHA and PWM) and antigens (PPD, C. albicans, S. aureus,
and tetanus toxoid) were all within normal limits. Histo-
pathology and flow analysis of the bone marrow aspirate
demonstrated a normal bone marrow with stimulated
thrombopoiesis but without the existence of clonality or
malignancy. Additional flow analyses of the bone marrow
aspirate demonstrated abnormal distribution of B cells with
increased fraction of CD19+ CD20- and absence of IgD-
IgM- CD27+ memory B cells (Additional file 2: Figure S1).
Other data
Complement activation, including classical-, alternative-,
and lectine pathways, were all normal.
Molecular biology analyses
By Ig gene rearrangement analysis no evidence of clo-
nality was observed in the unfractionated B-cells or in
B-cell subsets obtained by FACS. Somatic hypermutation
within immunoglobulin kappa gene transcripts was not
detected, although the result was uncertain due to very
low numbers of B cells. Mutations associated with CVID
were not demonstrated in either ICOS or TACI, and
other potential mutations within BAFF-R, CD19, CD20
or CD81 were not analyzed.
Based on the results of these immunological analyses,
particularly the low number of isotype- switched memory
B cells, a presumptive diagnosis of CVID was made.
Within CVID classification systems, the patient fulfilled
the criteria for Freiburg type Ia and EUROClass group
smB-Tr(high) CD21(low). In February 2011 subcutaneous
immunoglobulin replacement therapy was initiated with
Subcuvia 60 mL weekly and within three months of treat-
ment his IgG level had risen to 7.6 g/L. In June 2011
flow cytometric evaluation of B and T cell subsets was
performed, demonstrating a persistently significantly re-
duced fraction of isotype-switched memory B cells of 0.1%,
although his total circulating CD19+ B lymphocyte count
had risen to 1089 cells × 106/L (21.3% of total lympho-
cytes) compared to 285 cells × 106/L (12.1% of totallymphocytes) in January 2011 (Additional file 1: Table S1).
Currently as of October 2012, he is doing well, does not
experience increased frequency of bacterial infections re-
ceiving 60 mL subcutaneous immunoglobulin weekly
(obtaining an IgG level ranging between 8 g/L and 10 g/L).
Importantly, he preserves a normal thrombocyte count of
335 × 109 cells/L more than three years after Rituximab
treatment for ITP.
Discussion
Here, we present the medical history of a patient with
treatment refractory ITP and persistent lymphadenopathy
diagnosed at the age of 11-years, who was splenectomized
and received multiple courses of high-dose corticosteroid
before he was eventually treated with Rituximab resulting
in a sustained response with normalization of thrombocyte
counts. However, in the setting of severe pneumococcal
meningitis, hypogammaglobulinemia was diagnosed, and
an extensive immunological investigation was performed
in order to characterize the immune status of the patient,
and to distinguish between a primary immunodeficiency
and a side effect of Rituximab treatment.
Common variable immunodeficiency
The hallmark of CVID is increased susceptibility to bacter-
ial respiratory tract infections caused by reduced levels of
serum immunoglobulins. CVID is defined as significantly
reduced levels of IgG and decreased levels of IgA and/or
IgM together with an absence of iso-haemagglutinins and/
or inappropriate responses to pneumococcal vaccination
[1,2]. Several different classification systems have been de-
veloped in order to divide this broad spectrum of immuno-
deficiencies into biologically and clinically meaningful
groups predicting severity of disease, treatment response,
and prognosis [7,8]. The Freiburg classification allows a
division of patients into three distinct groups and empha-
sizes that the central characteristic of CVID is lack of
switched memory B cells (IgD- IgM- CD27+) [8,9], which
is associated with the development of autoimmunity,
lymphoid hyperplasia, splenomegaly, and granulomatous
disease [10,11] and therefore a major determinant of dis-
ease severity. Another aspect of CVID is that somatic
hypermutation is impaired in B cells of about 70% of pa-
tients, thus interfering with the production of highly spe-
cific antibodies [12]. Although CVID primarily affects the
B cell population and immunoglobulin synthesis, it may
also influence T cell immunity. Numerous abnormalities in
the T cell compartment have been reported in CVID
patients, including T lymphopenia, decreased CD4 +
CD45RA +T cells, a restricted T cell repertoire, accelerated
T cell death, and impaired cytokine production [13]. As to
the origin of CVID, a number of genetic defects, including
mutations in TACI, ICOS, BAFF-R, CD19, CD20, and
CD81, which are all molecules involved in differentiation,
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These only account for a minority of CVID cases (about
15-20%), and the molecular pathophysiology of the
remaining fraction has remained largely obscure [14]. Re-
cently, however, a genome-wide association study has
added novel mutations to this list by identifying diverse
causes of CVID [15]. Taken together, CVID cannot simply
be characterized as a condition of impaired immune re-
sponses, but should rather be viewed as state of aberrant
immunity.
Autoimmunity in CVID
A substantial proportion of patients with CVID also ex-
perience autoimmune manifestations, ranging from 22% to
48% in different studies, which is associated with the pres-
ence of granulomatous disease and TACI mutations [3,7].
Among autoimmune conditions associated with CVID,
cytopenias are particularly common, often present together
with splenomegaly [7]. In different case series, ITP has
been diagnosed in 7% to 20% of patients with CVID
[7,16,17]. In the context of the present case it is notable
that the diagnosis of ITP and/or AIHA frequently precedes
that of CVID, which was indeed the case in 54% of patients
in one study [16] and in 62% in another study [17]. Besides
ITP and AIHA, other hematologic manifestations overrep-
resented among CVID patients are polyclonal lymphocytic
infiltration and lymphoid malignancy, each of which is
positively correlated with the serum IgM level [7]. Several
hypotheses have been presented to explain the increased
frequency of autoimmune manifestations in CVID. Given
that both defective B cell class-switch and loss of somatic
hypermutation are correlated to autoimmunity it has been
suggested that such molecular alterations may explain the
inability to exclude autoreactive B cell clones [13].
Clinical use of Rituximab
Rituximab is an anti-CD20 humanized chimeric monoclo-
nal antibody and was initially developed to treat B cell ma-
lignancies [4,18]. Following initial success, Rituximab has
also been approved for the management of rheumatoid
arthritis and has undergone clinical trials demonstrating
the successful use in a growing number of autoimmune
diseases, including systemic lupus erythematosis, ITP, pem-
phigus, multiple sclerosis, and ANCA-associated vasculitis
[19-23], in which dysregulated B cells are involved in the
pathogenesis. A systematic review on the utilization of ri-
tuximab in ITP was published in 2007, included 313 pa-
tients from a total of 19 (eligible) studies and reported an
overall response rate of 62.5% (as defined by a platelet
increase to >50 × 109 cells/L) when given at a dose of
375 mg/m2 iv once weekly for 4 weeks [24]. The median
duration of the response was 10.5 months [24]. More re-
cent reports indicate that Rituximab may be more effective
than various other immunosuppressants, particularly in thesetting of refractory cases of ITP. Accordingly, Rituximab
has been recognized as a useful drug in the second line of
treatment for ITP either alone or in combination with cor-
ticosteroid, although it is not recommended as standard
first-line therapy [25]. However, whereas initial response
rates are high, long-term follow up data on patients treated
with Rituximab are sparse. It is still under investigation,
how patients should be monitored and how frequently
treatment should be repeated. In general, Rituximab is con-
sidered a relatively safe drug with only modest toxicity and
infectious complications [4]. Among side effects described
are infusion-related reactions, serum sickness, and agra-
nulocytosis [19,26]. Due to the depletion of the B cell-
mediated arm of the immune system, infections are a
major concern. In different studies, the rate of serious in-
fections has been between 2.8% to 45% (mean 12%) and
the use of Rituximab as a direct cause of death has been
estimated to 7% [27]. These numbers may be difficult to
interpret, since most of the patients were immuno-
compromised even prior to Rituximab treatment due to
autoimmunity and the concomitant use of additional im-
munosuppressive agents. A recent multicenter retrospec-
tive study on the use of Rituximab in CVID-associated
immune cytopenias reported a response rate of 85%, in-
cluding 74% complete responses. However, after a mean
follow-up time of 30 months after Rituximab, 10 out of
the initial reponders relapsed and required re-treatment,
and severe infections occurred in 24% [28].
Mechanism of action of Rituximab
Rituximab targets CD20 expressed by human B cells and a
small subset of T cells [29,30]. Within the B cell compart-
ment, the large majority of B cells, with the exception of
stem cells, pro-B cells, and plasma cells, express CD20
and therefore represent targets of Rituximab [31]. Binding
to CD20 by Rituximab induces B cell depletion by
complement- and antibody-mediated cytotoxicity resulting
in a 90% reduction in the number of CD20+ B cells in per-
ipheral blood, lymphoid tissue, and bone marrow [32].
The rationale behind using Rituximab in malignant and
autoimmune diseases is therefore to eradicate malignant B
cell clones or to prevent production of auto-antibodies by
auto-reactive short-lived plasma cells derived from CD20
expressing B cells, respectively [4]. Furthermore, several
lines of evidence suggest that the T cell compartment may
be modulated as well, including reduction of antigen-
presenting cells to pathogenic auto-reactive T cells and
modulation of the regulatory T cell compartment [4].
Whereas transient depletion of peripheral B cells is com-
mon, Rituximab generally does not result in a decrease in
immunoglobulin levels [4], a property that has been hy-
pothesized to be attributable to the presence of long-lived
plasma cells [33]. However, low immunoglobulin levels
can occur, and in rare cases Rituximab may result in low
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study involving Rituximab treatment of patients with
rheumatoid arthritis, the incidence of decreased IgM
was 40% whereas low IgG was seen in 3-6% of patients
following the 5th cycle of Rituximab [34]. In addition rare
cases have been published describing profound hypo-
gammaglobulinemia seven years after treatment for indo-
lent lymphoma [35] as well as hypogammaglobulinemia
with selective delayed recovery in memory B cells after ad-
juvant Rituximab treatment for NHL [36].
Previous cases of hypogammaglobulinemia associated
with Rituximab treatment
Even if Rituximab only infrequently affects immuno-
globulin levels, a central question is whether Rituximab
may aggravate pre-existing CVID. Given that both CVID
and Rituximab treatment result in loss of memory B
cells and possibly affect the T cell population as well, it
may be difficult to distinguish between the different
origins of hypogammaglobulinemia. This issue was
addressed by Diwakar et al., who described two patients
presenting with aggravated immunodeficiency and bac-
terial infection requiring immunoglobulin infusions sev-
eral months after Rituximab treatment for ITP [37], and
therefore a very similar scenario to our case. This led the
authors to suggest that Rituximab may have accelerated the
presentation of immunodeficiency, since these patients had
no notable infections prior to treatment but both experi-
enced significant clinical deterioration, one of which was
fatal, shortly after receiving Rituximab [37]. In addition, one
report describing persistent pan-hypogammaglobulinemia
after Rituximab treatment for post-transplant EBV-
associated AIHA may also represent Rituximab-induced
aggravation of CVID [38].
So should Rituximab always be avoided in patients
with ITP, in whom CVID has been diagnosed or is
suspected? Several reports suggest that this may not be
the case [39-42]. In the first case, a 34-year-old male
with CVID complicated by inflammatory bowel disease,
hepatic hyperplasia, splenomegaly, and portal hyperten-
sion, obtained a partial response for at least 11 months,
and the authors were the first to suggest that treatment
with Rituximab might be an option for patients with
CVID and ITP refractory to other treatments (or for
those in whom splenectomy is contraindicated) [39]. Al-
Ahmad et al. described the successful use of Rituximab
in a patient with refractory ITP and CVID [40]. This pa-
tient, a 36-year-old female with associated lymphaden-
opathy, EBV vireamia, and bronchiectatic changes
received Rituximab for ITP and experienced a good re-
sponse, even though she had a well-recognized CVID. In
the next case concerning a 19-year-old woman with
CVID complicated by granulomatous disease, neutro-
penia, and refractory ITP, a full response to Rituximabtreatment was achieved with effect at 12 months in com-
bination with low-dose steroid [41]. Finally, El-Shanawany
et al. described a case of a 65-year-old woman with CVID
and severe recurrent thrombocytopenia despite treatment
with high-dose IVIG and splenectomy, who had an excel-
lent response to Rituximab therapy with disappearance
of anti-platelet antibodies as reported 12 months after Ri-
tuximab [42]. However, in none of these cases did
hypogammaglobulinemia occur as a direct side effect to
Rituximab, as these patients were all diagnosed with CVID
prior to Rituximab and, notably, all of these patients re-
ceived IVIG concomitantly with and after Rituximab treat-
ment. In line with these case reports Gobert et al.
described the results of a multicenter retrospective study
concerning the use of Rituximab in 33 patients with
CVID-associated immune cytopenias and found that Ri-
tuximab was associated with a subsequent decrease in re-
sidual IgG in individuals not receiving IgG replacement
therapy [24]. Furthermore, 24% of individuals developed
severe infections after Rituximab treatment, and this was
more frequently observed in those not receiving IgG re-
placement therapy. One splenectomized adult, who did
not receive IgG replacement, died from S. pneumoniae
pneumonia with sepsis 4 months after Rituximab treat-
ment, underscoring the importance of addressing the po-
tential development of severe hypogammaglobulinemia in
patients with CVID treated with Rituximab.
Pathogenesis of the development of
hypogammaglobulinemia in the presented patient
We initially considered whether this patient’s hypo-
gammaglobulinemia might be a direct consequence of Ri-
tuximab treatment, which he had received about 21
months prior to his presentation with pneumococcal men-
ingitis. However, based on his past medical history, which
included treatment resistant ITP, splenomegaly, persistent
lymphadenopathy, chronic gastrointestinal complaints, in-
sufficient antibody responses to pneumococcal vaccin-
ation, and decreased IgA levels, we speculated that his ITP
might rather be an autoimmune manifestation of an
underlying CVID. This hypothesis was supported by the
immunological characterization demonstrating a very low
fraction of isotype-switched memory B cells (IgM- IgD-
CD27+) in agreement with a diagnosis of CVID Freiburg
class Ia. However, it should be noted that decreased num-
bers of isotype-switched memory B cells may rarely be
secondary to Rituximab [31]. Although we demonstrated
neither TACI/ICOS mutations nor the absence of somatic
hypermutation, CVID is a highly heterogeneous entity and
these defects are only a few among several possible genetic
abnormalities, which may be present in CVID. Based
on the current knowledge on immunological effects
of Rituximab, we do not believe that the concept of
hypogammaglobulinemia arising as a direct effect of
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However, since this patient’s hypogammaglobulinemia be-
came manifest and the frequency of infections increased
following Rituximab infusions, it is possible that Rituxi-
mab was the factor that unmasked the full phenotype of
an underlying CVID. In fact it was only after Rituximab
treatment that he fulfilled the criteria defining CVID, in
particular with respect to decreased IgG levels [2]. Import-
antly, he did not have any condition that excludes the
diagnosis of CVID. It seems that the immunodeficiency
became more dominant than the autoreactivity (ITP), both
present in severe cases of CVID, following Rituximab
treatment.
Due to the raised fraction of CD3+ TCRαβ +CD4- CD8-
double negative T cells in peripheral blood, the possibility
of autoimmune lymphoproliferative syndrome (ALPS)
was also considered. ALPS is characterized by benign
lymphoproliferative disease and autoimmune cytopenia
with a functional defect of T cells in FAS-induced apop-
tosis/CD95 signaling and therefore has considerable clinical
and immunological overlap with CVID [43]. However, in
contrast to the case presented here, ALPS is generally char-
acterized by hypergammaglobulinemia, although a minority
of patients may present with hypogammaglobulinemia [44].
ALPS patients also display a distinct pattern of biomarkers,
including elevated soluble FasL and IL-10, which we did
not find, and have a less pronounced decrease in isotype-
switched memory B cells than CVID patients. Finally, we
cannot exclude a possible minor effect of the patient’s
splenectomy at age 11 on the distribution of lymphocyte
subpopulations measured by flow cytometry on peripheral
blood [45], although we do not find it likely to account for
the significant abnormalities, including absence of isotype-
switched memory B cells.
Conclusion
Taken together, we believe that the scenario that most
precisely describes the clinical picture and immuno-
logical status in this patient is a diagnosis of underlying
CVID, possibly aggravated by Rituximab. We recom-
mend that all patients with ITP/AIHA should have their
immunoglobulin levels measured repeatedly and be
tested for CVID. Awareness of the association of CVID
with autoimmune cytopenias is particularly important,
since ITP/AIHA may often be diagnosed before the
presence of hypogammaglobulinemia and thus be the
presenting manifestation of CVID. This important point
has been previously evidenced by several studies [13,46]
and is also in line with the conclusions of a recent article
discussing the same issue in patients with autoimmune
cytopenias and underlying CVID or ALPS [47]. The case
presented here together with other reports clearly illustrate
that individuals with disturbed humoral immunity may be
particularly sensitive to Rituximab [28]. In consideration ofthe well-established relationship between CVID and ITP,
we recommend that humoral immunity, i.e. immunoglobu-
lin levels, be examined before and after initiating Rituxi-
mab therapy. Rituximab treatment of patients with CVID
and ITP does not seem to be contraindicated but should
at least be accompanied by immunoglobulin replacement
therapy during and after treatment [28,37]. In the future,
it will be interesting to obtain further knowledge on
whether Rituximab can be used effectively and safely in
patients with CVID and ITP and to further explore the
immunological effects of this potent therapeutic antibody.
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